Elva Morretta

Dr. Elva Morretta

Farmacia, Università degli studi Napoli "Federico II", Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Michele BiagioliMichele Biagioli
Michele Biagioli
CGCristina Di Giorgio
Cristina Di Giorgio
CMCarmen Massa
Carmen Massa
SMSilvia Marchianò
Silvia Marchianò
RBRachele Bellini
Rachele Bellini
Stefano FiorucciStefano Fiorucci
Stefano Fiorucci
The interplay between the dysbiotic microbiota and bile acids is a critical determinant for development of a dysregulated immune system in inflammatory bowel disease (IBD). Here we have investigated the fecal bile acid metabolome, gut microbiota composition, and immune responses in IBD patients and murine models of colitis and found that IBD associates with an elevated excretion of primary bile acids while secondary, allo- and oxo- bile acids were reduced. These changes correlated with the disease severity, mucosal expression of pro-inflammatory cytokines and chemokines, and reduced inflow of anti-inflammatory macrophages and Treg in the gut. Analysis of bile acids metabolome in the feces allowed the identification of five bile acids: 3-oxo-DCA, 3-oxo-LCA, allo-LCA, iso-allo-LCA and 3-oxo-UDCA, whose excretion was selectively decreased in IBD patients and diseased mice. By transactivation assay and docking calculations all five bile acids were shown to act as GPBAR1 agonists and RORγt inverse agonists, skewing Th17/Treg ratio and macrophage polarization toward an M2 phenotype. In a murine model of colitis, administration of 3-oxo-DCA suffices to reverse colitis development and intestinal dysbiosis in a GPBAR1-dependent manner. In vivo administration of 3-oxo-DCA to colitic mice also reverses disease severity and RORγt activation induced by a RORγt agonist and IL-23, a Th17 inducing cytokine. These results demonstrated that intestinal excretion of 3-oxoDCA, a dual GPBAR1 agonist and RORγt inverse agonist, is reduced in IBD and in models of colitis and its restitution protects against colitis development, highlighting a potential role for this agent in IBD management.

1 September 2020 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
ACAdriana Carino
Adriana Carino
MBMichele Biagioli
Michele Biagioli
SMSilvia Marchianò
Silvia Marchianò
CFChiara Fiorucci
Chiara Fiorucci
MBMartina Bordoni
Martina Bordoni
Stefano FiorucciStefano Fiorucci
Stefano Fiorucci

21 May 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
ACAdriana Carino
Adriana Carino
SMSilvia Marchianò
Silvia Marchianò
Michele BiagioliMichele Biagioli
Michele Biagioli
CFChiara Fiorucci
Chiara Fiorucci
AZAngela Zampella
Angela Zampella
Stefano FiorucciStefano Fiorucci
Stefano Fiorucci
Non-alcoholic steatohepatitis (NASH) is a progressive, chronic, liver disease whose prevalence is growing worldwide. Despite several agents being under development for treating NASH, there are no drugs currently approved. The Farnesoid-x-receptor (FXR) and the G-protein coupled bile acid receptor 1 (GPBAR1), two bile acid activated receptors, have been investigated for their potential in treating NASH. Here we report that BAR502, a steroidal dual ligand for FXR/GPBAR1, attenuates development of clinical and liver histopathology features of NASH in mice fed a high fat diet (HFD) and fructose (F). By RNAseq analysis of liver transcriptome we found that BAR502 restores FXR signaling in the liver of mice feed HFD–F, and negatively regulates a cluster of genes including Srebf1 (Srepb1c) and its target genes—fatty acid synthase (Fasn) and Cell death-inducing DFF45-like effector (CIDE) genes, Cidea and Cidec—involved in lipid droplets formation and triglycerides storage in hepatocytes. Additionally, BAR502 increased the intestinal expression of Fgf15 and Glp1 and energy expenditure by white adipose tissues. Finally, exposure to BAR502 reshaped the intestinal microbiota by increasing the amount of Bacteroidaceae. In conclusion, we have shown that dual FXR/GPBAR1 agonism might have utility in treatment of NASH.

5 December 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
SMSilvia Marchianò
Silvia Marchianò
Michele BiagioliMichele Biagioli
Michele Biagioli
MBMartina Bordoni
Martina Bordoni
Elva MorrettaElva Morretta
Elva Morretta
CGCristina Di Giorgio
Cristina Di Giorgio
Stefano FiorucciStefano Fiorucci
Stefano Fiorucci
Background: Patients with nonalcoholic fatty liver disease are at increased risk to develop atherosclerotic cardiovascular diseases. FXR and GPBAR1 are 2 bile acid–activated receptors exploited in the treatment of nonalcoholic fatty liver disease: whether dual GPBAR1/FXR agonists synergize with statins in the treatment of the liver and cardiovascular components of nonalcoholic fatty liver disease is unknown. Methods and Results: Investigations of human aortic samples obtained from patients who underwent surgery for aortic aneurysms and Gpbar1 −/− , Fxr −/− , and dual Gpbar1 −/‐ Fxr −/− mice demonstrated that GPBAR1 and FXR are expressed in the aortic wall and regulate endothelial cell/macrophage interactions. The expression of GPBAR1 in the human endothelium correlated with the expression of inflammatory biomarkers. Mice lacking Fxr and Gpbar1 −/− / Fxr −/− display hypotension and aortic inflammation, along with altered intestinal permeability that deteriorates with age, and severe dysbiosis, along with dysregulated bile acid synthesis. Vasomotor activities of aortic rings were altered by Gpbar1 and Fxr gene ablation. In apolipoprotein E −/− and wild‐type mice, BAR502, a dual GPBAR1/FXR agonist, alone or in combination with atorvastatin, reduced cholesterol and low‐density lipoprotein plasma levels, mitigated the development of liver steatosis and aortic plaque formation, and shifted the polarization of circulating leukocytes toward an anti‐inflammatory phenotype. BAR502/atorvastatin reversed intestinal dysbiosis and dysregulated bile acid synthesis, promoting a shift of bile acid pool composition toward FXR antagonists and GPBAR1 agonists. Conclusions: FXR and GPBAR1 maintain intestinal, liver, and cardiovascular homeostasis, and their therapeutic targeting with a dual GPBAR1/FXR ligand and atorvastatin holds potential in the treatment of liver and cardiovascular components of nonalcoholic fatty liver disease.

8 May 2019 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
SVStefano De Vuono
Stefano De Vuono
MRMaria Anastasia Ricci
Maria Anastasia Ricci
EMElisa Nulli Migliola
Elisa Nulli Migliola
MMMaria Chiara Monti
Maria Chiara Monti
Elva MorrettaElva Morretta
Elva Morretta
GLGraziana Lupattelli
Graziana Lupattelli

13 October 2017 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Elva MorrettaElva Morretta
Elva Morretta
RERoberta Esposito
Roberta Esposito
Festa CarmenFesta Carmen
Festa Carmen
Raffaele RiccioRaffaele Riccio
Raffaele Riccio
Agostino CasapulloAgostino Casapullo
Agostino Casapullo
Maria Chiara MontiMaria Chiara Monti
Maria Chiara Monti
Sinuleptolide and its congeners are diterpenes with a norcembranoid skeleton isolated from the soft coral genus Sinularia. These marine metabolites are endowed with relevant biological activities, mainly associated with cancer development. 5-epi-sinuleptolide has been selected as a candidate for target discovery studies through the application of complementary proteomic approaches. Specifically, a combination of conventional chemical proteomics based on affinity chromatography, coupled with high-resolution mass spectrometry and bioinformatics, as well as drug affinity responsive target stability (DARTS), led to a clear identification of actins as main targets for 5-epi-sinuleptolide. Subsequent in-cell assays, performed with cytochalasin D as reference compound, gave information on the ability of 5-epi-sinuleptolide to disrupt the actin cytoskeleton by loss of actin fibers and formation of F-actin amorphous aggregates. These results suggest the potential application of 5-epi-sinuleptolide as a useful tool in the study of the molecular processes impaired in several disorders in which actin is thought to play an essential role.